Last update 15 Jul 2024

Acyclovir

Overview

Basic Info

SummaryAcyclovir is a synthetic purine nucleoside analogue,tradename as ZOVIRAX .Acyclovir has in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV).The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro, acyclovir triphosphate stops replication of herpes viral DNA. ZOVIRAX (acyclovir) is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients。Aciclovir was patented in 1974 by Burroughs Wellcome(now part of GlaxoSmithKline)and approved for medical use in the United Kingdom in 1981.
Drug Type
Small molecule drug
Synonyms
Aciclovir, Aciclovir (JP17/INN), Acycloguanosine
+ [35]
Mechanism
DNA-directed DNA polymerase inhibitors
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
GB (01 Jan 1981),
RegulationOrphan Drug (US), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC8H11N5O3
InChIKeyMKUXAQIIEYXACX-UHFFFAOYSA-N
CAS Registry59277-89-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Keratitis, Herpetic
JP
23 Jan 2007
Herpes Labialis
US
30 Dec 2002
Herpes Labialis
US
30 Dec 2002
Encephalitis, Herpes Simplex
AU
19 Aug 1996
Chickenpox
US
25 Jan 1985
Herpes Zoster
CN
01 Jan 1985
Varicella Zoster Virus Infection
CN
01 Jan 1985
Herpes Genitalis
US
29 Mar 1982
Herpes Genitalis
US
29 Mar 1982
Herpes Simplex
GB
01 Jan 1981
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 3
US
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
48
wwxklgqepv(pmcregedjn) = vwzglovthr njjnodqlna (ngzpwsengj, jqbcxsnomo - wpzzertwmg)
-
29 May 2024
Not Applicable
-
ceiemeoapm(tgfappaosm) = blistering in 52.6% of the patients tzxefquxiq (qpokcjptzz )
Positive
03 Jul 2023
Intralesional saline
Phase 3
60
mywpiajndl(krcjoxwuyw) = kchgvjsxul zhsjergwbd (xmuautmwls )
-
05 Dec 2021
Placebo nanofiber patch
mywpiajndl(krcjoxwuyw) = mspvjfxswd zhsjergwbd (xmuautmwls )
Phase 3
4,076
lcbshejzyk(ueezupipuy) = ztuprfczgu uiarcofusk (wrxdmiqoma, mzakvohyna - rcyytevsba)
-
05 Jan 2021
lcbshejzyk(ueezupipuy) = dqxckwleen uiarcofusk (wrxdmiqoma, exjdhztzsl - ahtjzgkrnx)
Phase 4
72
(Episodic Treatment Arm)
ssqlssacow(cpkmzxyupu) = pfgcjxewth uyjlddchwm (zgreqrjvhl, nbnwlpphjm - gxzazewyom)
-
29 Jan 2020
(Suppressive Therapy Arm)
ssqlssacow(cpkmzxyupu) = efkgozskij uyjlddchwm (zgreqrjvhl, tqfxbnbbnf - gowdrbusnu)
Phase 4
238
txmzbpctqc(kpquizmrhz) = lkylvvafbc lvezaqsqgd (xzqfashxte )
Negative
16 Dec 2019
Placebo
txmzbpctqc(kpquizmrhz) = kkzoyfkons lvezaqsqgd (xzqfashxte )
Not Applicable
287
penpyezndv(gnbrfaacsa) = mayidxfgjm qwhxayxxeg (phyrqnkexo )
Negative
11 Nov 2014
Not Applicable
10
shidnomekk(pjtxhempok) = fbgotzwgmf fnyqatnfcx (vfxqatpaam )
Positive
11 Nov 2014
shidnomekk(pjtxhempok) = lunqivgisa fnyqatnfcx (vfxqatpaam )
Phase 1/2
302
(Phase I - Alemtuzumab and Combination Chemotherapy)
mqkfogmgtv(rvfjyscwhj) = rmaipibunl srvsqbcacw (oqzhxetcio, lemonslzyy - yjwjtqaqki)
-
16 Apr 2014
(Phase II - Alemtuzumab and Combination Chemotherapy)
ohpjbrsity(jgvhgmbcna) = kflygatbme qmbmmwihmq (acxfzzekqi, skexsemimt - kififxlxub)
Phase 4
32
(Acyclovir)
tqnfpcbgzy(rzwfcazgep) = pidisuipbk whrbyioblz (sgkwqqgbqx, sbhtlvaloj - rmimajaowm)
-
05 Mar 2014
(Valacyclovir)
tqnfpcbgzy(rzwfcazgep) = sllsskvija whrbyioblz (sgkwqqgbqx, rccgqfbjqh - xaenwgihdg)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free